Timothy A Chan

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management
    Allen S Ho
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Onco Targets Ther 6:223-32. 2013
  2. pmc Resistance to EGFR inhibitors: Molecular determinants and the enigma of head and neck cancer
    Luc G T Morris
    Human Oncology and Pathogenesis Program, Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, NY, USA Timothy A Chan Human Oncology and Pathogenesis Program, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, NY, USA
    Oncotarget 2:894-5. 2011
  3. doi request reprint Epigenetic biomarkers
    Timothy A Chan
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Curr Top Microbiol Immunol 355:189-216. 2012
  4. pmc Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene
    Maria Meehan
    Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Dublin, Ireland
    Mol Cancer 11:6. 2012
  5. doi request reprint IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma
    Daniel Gorovets
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 18:2490-501. 2012
  6. pmc An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
    Dan Rohle
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 340:626-30. 2013
  7. pmc IDH mutation impairs histone demethylation and results in a block to cell differentiation
    Chao Lu
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 483:474-8. 2012
  8. pmc The mutational landscape of adenoid cystic carcinoma
    Allen S Ho
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Nat Genet 45:791-8. 2013
  9. pmc Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
    Kasthuri Kannan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Oncotarget 3:1194-203. 2012
  10. doi request reprint Valproic acid use during radiation therapy for glioblastoma associated with improved survival
    Christopher A Barker
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 86:504-9. 2013

Detail Information

Publications32

  1. pmc Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management
    Allen S Ho
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Onco Targets Ther 6:223-32. 2013
    ..Here, we review recent progress in epigenetic treatments and consider their implications for future cancer therapy...
  2. pmc Resistance to EGFR inhibitors: Molecular determinants and the enigma of head and neck cancer
    Luc G T Morris
    Human Oncology and Pathogenesis Program, Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, NY, USA Timothy A Chan Human Oncology and Pathogenesis Program, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, NY, USA
    Oncotarget 2:894-5. 2011
    ..With additional clinical investigation, these findings may open the door to the possibility of PTPRS status serving as a biomarker for drug resistance, analogous to EGFR or KRAS resistance mutations in lung and colorectal cancer...
  3. doi request reprint Epigenetic biomarkers
    Timothy A Chan
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Curr Top Microbiol Immunol 355:189-216. 2012
    ..The recent application of global analysis strategies has further accelerated our understanding of the epigenome and promises to enhance the identification of epigenomic programs underlying cancer progression and treatment response...
  4. pmc Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene
    Maria Meehan
    Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Dublin, Ireland
    Mol Cancer 11:6. 2012
    ..The molecular mechanism, however, by which PTPRD renders a tumor suppressor effect in neuroblastoma is unknown...
  5. doi request reprint IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma
    Daniel Gorovets
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 18:2490-501. 2012
    ..Accordingly, we sought to identify and characterize clinically relevant molecular subclasses of lower grade diffuse astrocytic gliomas...
  6. pmc An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
    Dan Rohle
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 340:626-30. 2013
    ..These data suggest that mIDH1 may promote glioma growth through mechanisms beyond its well-characterized epigenetic effects...
  7. pmc IDH mutation impairs histone demethylation and results in a block to cell differentiation
    Chao Lu
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 483:474-8. 2012
    ..Together these data demonstrate that 2HG can inhibit histone demethylation and that inhibition of histone demethylation can be sufficient to block the differentiation of non-transformed cells...
  8. pmc The mutational landscape of adenoid cystic carcinoma
    Allen S Ho
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Nat Genet 45:791-8. 2013
    ..Collectively, our observations establish a molecular foundation for understanding and exploring new treatments for ACC. ..
  9. pmc Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
    Kasthuri Kannan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Oncotarget 3:1194-203. 2012
    ..In summary, our findings both identify ATRX mutation as a defining molecular determinant for a large subset of IDH-mutant gliomas and have direct implications on pathogenic mechanisms across the wide spectrum of LGGs...
  10. doi request reprint Valproic acid use during radiation therapy for glioblastoma associated with improved survival
    Christopher A Barker
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Int J Radiat Oncol Biol Phys 86:504-9. 2013
    ..We investigated whether VA use during RT for GB was associated with overall survival (OS)...
  11. ncbi request reprint Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma
    Naamit K Gerber
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
    Int J Radiat Oncol Biol Phys 89:322-9. 2014
    ..However, given the activity of EGFR tyrosine kinase inhibitors in the central nervous system, it is uncertain whether upfront brain RT is necessary for patients with EGFR-mutant lung adenocarcinoma with BM...
  12. pmc Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Antonio Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 15:242-50. 2013
    ..In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)...
  13. pmc Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation
    Luc G T Morris
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Genet 45:253-61. 2013
    ..Loss of FAT1 function is a frequent event during oncogenesis. These findings address two outstanding issues in cancer biology: the basis of Wnt activation in non-colorectal tumors and the identity of a 4q35 tumor suppressor...
  14. doi request reprint MRI perfusion in determining pseudoprogression in patients with glioblastoma
    Robert J Young
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Imaging 37:41-9. 2013
    ..001), and higher PSR (P=.039) than progression. DSC MRI perfusion successfully identified pseudoprogression in patients who did not require a change in treatment despite radiographic worsening following chemoradiotherapy...
  15. doi request reprint Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma
    Daniel E Spratt
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 22, New York, NY, 10065, USA
    J Neurooncol 116:357-63. 2014
    ..Our data does not support the OS benefit previously seen in delayed RT when correcting for important covariates. We demonstrate a survival detriment with delaying RT post-surgery greater than 6 weeks on multivariate analysis...
  16. doi request reprint A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases
    Cameron Brennan
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York
    Int J Radiat Oncol Biol Phys 88:130-6. 2014
    ..To evaluate local control after surgical resection and postoperative stereotactic radiosurgery (SRS) for brain metastases...
  17. doi request reprint Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy
    Ian Ganly
    Memorial Sloan Kettering Cancer Center Human Oncology and Pathogenesis Program, 1275 York Avenue, New York, New York 10065, USA
    J Clin Endocrinol Metab 98:E962-72. 2013
    ..Hurthle cell cancer (HCC) is an understudied cancer with poor prognosis...
  18. pmc Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease
    Iñigo Landa
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Clin Endocrinol Metab 98:E1562-6. 2013
    ..Telomerase activity is required for cell immortalization. Somatic TERT promoter mutations modifying key transcriptional response elements were recently reported in several cancers, such as melanomas and gliomas...
  19. doi request reprint Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status
    Marsha Reyngold
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Neurooncol 110:369-74. 2012
    ..Grade 3-4 hematologic toxicity occurred in 11 patients. Abbreviated RT with concurrent TMZ provides a clinical benefit, is safe and tolerable in patients of advanced age or poor functional status...
  20. pmc Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine
    Sevin Turcan
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Oncotarget 4:1729-36. 2013
    ..These findings have substantial impact for exploring new treatment strategies for patients with IDH mutant gliomas. ..
  21. pmc Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis
    Berenice Ortiz
    Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065 Human Oncology and Pathogenesis Program
    Proc Natl Acad Sci U S A 111:8149-54. 2014
    ....
  22. pmc IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
    Sevin Turcan
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Nature 483:479-83. 2012
    ....
  23. pmc Driver mutations of cancer epigenomes
    David M Roy
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
    Protein Cell 5:265-96. 2014
    ..Understanding how genetic alterations give rise to the cancer epigenome will offer new possibilities for developing better prognostic and therapeutic strategies. ..
  24. ncbi request reprint Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins
    Yongxing Gong
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Genet 46:588-94. 2014
    ..Thus, PARK2 regulates cyclin-CDK complexes, as does the CDK inhibitor p16, but acts as a master regulator of the stability of G1/S cyclins...
  25. pmc Genome sequencing identifies a basis for everolimus sensitivity
    Gopa Iyer
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 338:221. 2012
    ....
  26. doi request reprint MAPping the genomic landscape of low-grade pediatric gliomas
    Sevin Turcan
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Nat Genet 45:847-9. 2013
    ..These findings offer substantial insights that may spur the development of new diagnostics and treatments for these cancers. ..
  27. pmc Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers
    Luc G T Morris
    Human Oncology and Pathogenesis Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 108:19024-9. 2011
    ..These findings have important implications for our understanding of head and neck cancer tumorigenesis and for the use of targeted agents for this malignancy...
  28. pmc Comparative genomic analysis of primary versus metastatic colorectal carcinomas
    Efsevia Vakiani
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 30:2956-62. 2012
    ..To compare the mutational and copy number profiles of primary and metastatic colorectal carcinomas (CRCs) using both unpaired and paired samples derived from primary and metastatic disease sites...
  29. doi request reprint Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen
    Jana Jeschke
    Department of Surgery, Johns Hopkins University, Baltimore, MD, USA
    Epigenetics 7:701-9. 2012
    ..92) and validation cohort (HR = 2.87). Our study demonstrates an efficient method to utilize functional methylation changes in BC for the development of effective biomarkers for detection and prognosis prediction of BC...
  30. doi request reprint Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker
    M Catherine Pietanza
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Clin Cancer Res 18:1138-45. 2012
    ..This phase II study was conducted to assess the efficacy of temozolomide in patients with relapsed small cell lung cancer (SCLC)...
  31. pmc Breast cancer methylomes establish an epigenomic foundation for metastasis
    Fang Fang
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Sci Transl Med 3:75ra25. 2011
    ..These findings significantly enhance our understanding of breast cancer oncogenesis and aid the development of new prognostic biomarkers for this common malignancy...